# Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)

> **NCT07741838** · — · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 900 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07741838
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2028-07
- **Final completion:** 2029-03
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741838, "Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*